Clinical trials
Real World Study clinical trials
Below are recruiting real world study clinical trials, each written for real people, not researchers. We’re tracking 355 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07215975Recruiting
Luspatercept for adults with transfusion-dependent beta-thalassemia
This study looks at how well a medication called Luspatercept works for adults with transfusion-dependent beta-thalassemia, a blood condition that requires regular blood transfusions. Researchers want to understand how it helps people in the Middle East.
Seeb, Muḩāfaz̧at MasqaţAges 18 years+ - NCT06767891Enrolling by invitation
Real-world study of acalabrutinib for MCL or CLL
This study looks at how acalabrutinib works in real-world everyday medical practice for people with MCL or CLL who have already had at least one prior treatment. The goal is to see how well the drug performs outside of a strict research setting.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07741279Recruiting
Enarodustat for anemia in chronic kidney disease patients
This study tests a daily pill that helps people with chronic kidney disease and anemia make more red blood cells, which may reduce the need for other anemia treatments. It is for patients who are not on dialysis and do not plan to start dialysis or have a kidney transplant within the next six months.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT06819865Recruiting
EkoSonic device for acute pulmonary embolism in Chinese patients
This study tests if the EkoSonic device (used with a clot-busting medicine) is safe and effective for treating acute pulmonary embolism. It may be an option for people who have a large clot and an enlarged right heart chamber.
Guangzhou, GuangdongAges 18 years+ - NCT06183762Recruiting
Real-world study of treatments for MET-mutation lung cancer
This study looks at how different treatments work for people with advanced lung cancer that has a MET mutation. It aims to understand real-world treatment patterns and outcomes to help guide future care.
Changsha, HunanAges 18 years+ - NCT07064681Recruiting
AK104 plus TACE for resectable liver cancer
This trial tests whether adding an immunotherapy drug (AK104) to a standard liver cancer treatment (TACE) helps prevent the cancer from coming back after surgery. It is for people with early-stage liver cancer that can be surgically removed and who have a high risk of recurrence.
Guangzhou, GuangdongAges 18–75 - NCT07743944Recruiting
Breast cancer second-line treatment patterns in China
This study looks at how doctors in China treat hormone receptor-positive, HER2-negative breast cancer that has spread, when patients are starting their second line of therapy. The goal is to learn more about real-world treatment patterns and results, which may help you and your doctor make more informed treatment decisions.
Nanjing, JiangsuAges 18 years+ - NCT07302360Recruiting
Guselkumab for ulcerative colitis in Chinese patients
This study tracks how well guselkumab (Tremfya) works in real-world Chinese patients with moderate to severe ulcerative colitis who haven't tried advanced therapies before. It helps doctors understand how the drug performs outside of controlled trials.
BeijingAges 18 years+ - NCT07532863Recruiting
Heart Health Study for Newly Diagnosed Type 2 Diabetes
This study looks at how newly diagnosed type 2 diabetes affects heart and blood vessel health. Researchers will follow patients over time to understand the relationship between diabetes and cardiovascular risk.
Tangerang, BantenAges 40–70 - NCT07587723Recruiting
Real-world study of eltrombopag treatment in immune thrombocytopenia
This study looks at how doctors treat immune thrombocytopenia (ITP)—a blood condition where your body attacks its own platelets—using a drug called eltrombopag. Researchers want to understand treatment patterns and outcomes in real-world practice to improve care.
BaselAges 18–100 - NCT07619872Recruiting
Safety study of KONECT RESILIA heart valve replacement
This study tracks how well a new artificial aortic valve and aorta graft (called KONECT RESILIA) work after surgery in real-world patients. Researchers want to understand if it's safe and performs well over time in people who need this valve replaced.
München, BavariaAges 18 years+ - NCT07708935Recruiting
Study of young patients with solid tumors in China
This study looks at young people (40 or younger at diagnosis) with solid tumors in China. It aims to collect real-world information about their treatments and outcomes to find patterns that could help improve care.
ShanghaiAges 18–80 - NCT07543731Recruiting
Study of how patients stick with cholesterol-lowering injection medications
This study follows people who are starting one of three injectable cholesterol medications (inclisiran, evolocumab, or alirocumab) to see how well they stick with treatment over time. Understanding medication adherence helps doctors and patients find ways to improve long-term health outcomes.
BaselAges 18–99 - NCT04020536Recruiting
Real-world study for several infectious diseases
This study follows people with confirmed brucellosis, epidemic hemorrhagic fever, or kala-azar (visceral leishmaniasis) to understand how these infections behave in real life. It may help improve care by collecting evidence on diagnosis and treatment outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04025944Recruiting
Study of long-term hepatitis B or C infection
This study looks at people with hepatitis B or C infections that have lasted more than 6 months. It aims to better understand long-term management and how treatments may help over time.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04037995Recruiting
Real-world study of advanced liver disease in China
This study looks at people with very advanced liver problems to better understand what happens in real life. It may help doctors improve care for advanced cirrhosis and certain liver cancers.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04182984Recruiting
Compare immunosuppressant medicines for eye-only myasthenia gravis
This real-world study looks at how different immunosuppressant medicines work for people with non-thymoma ocular myasthenia gravis (eye symptoms due to MG). It may help doctors understand which treatments control symptoms best in everyday care.
Xi'an, ShaanxiAges 18–75 - NCT04286841Recruiting
Immunotherapy before lung surgery for early lung cancer
This trial looks at giving immunotherapy before surgery for certain early-stage lung cancers to help shrink the tumor and improve outcomes. It is mainly for people whose lung cancer can be removed by surgery and who don’t have specific gene changes like EGFR or ALK.
Guangzhou, GuangdongAges 18 years+ - NCT04716257Recruiting
Study of treatment outcomes in ovarian-spread colorectal cancer
This study follows women with colorectal cancer that has spread to the ovaries to see how care works in real life. It may help doctors understand which patients benefit most and how treatment choices affect outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT07600164RecruitingPhase 4
Real-world study of pyrotinib treatment for advanced HER2-positive breast cancer
This study follows patients with advanced breast cancer that has a protein called HER2 to see how well pyrotinib (a targeted drug) works when used in routine clinical practice. You'd be tracked over time to understand how this treatment affects your cancer and quality of life.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05387369Recruiting
Real-world study of Paxlovid for hospitalized COVID-19 patients
This study checks how Paxlovid works in everyday care for people who are hospitalized with confirmed COVID-19. If you have a positive COVID-19 test and mild to moderate symptoms, this trial may help doctors understand how well the treatment performs outside of tightly controlled settings.
ShanghaiAges 12 years+ - NCT05409482Recruiting
Areal-world test of camrelizumab plus apatinib for liver cancer
This study looks at how well a combination of camrelizumab and apatinib works for people with unresectable hepatocellular carcinoma (liver cancer you can’t remove with surgery). It is designed to see results in real-life care for patients who have limited options after standard treatment.
Fuzhou, FujianAges 18–75 - NCT05498064Recruiting
Study of ensartinib for advanced ALK-positive lung cancer
This real-world study looks at how ensartinib works in people with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has continued or worsened after ALK-targeted therapy. It may help doctors understand how well the treatment works and who benefits most in everyday care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05498675Recruiting
Sacubitril/valsartan study for high blood pressure by body size
This study tests how sacubitril/valsartan may affect heart function in people with high blood pressure, and whether results differ by body size (BMI). You may benefit by getting closer heart monitoring, though it depends on whether you fit the safety and medical criteria.
Beijing, Beijing MunicipalityAges 18–70
Hear when a new Real World Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for real world study?
- Yes. Clin2 currently lists 355 recruiting real world study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a real world study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a real world study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.